𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response

✍ Scribed by N. Viniou; E. Terpos; A. Galanopoulos; E. Kritikou-Griva; S. Akel; E. Michalis; E. Apostolidou; D. Georgiadou; A. Kouraklis; A. Parharidou; G. Kokkini; A. Symeonidis; N. Anagnostopoulos; J. Christakis; A. Tasiopoulou; D. Loukopoulos; X. Yataganas

Publisher
Springer
Year
2002
Tongue
English
Weight
36 KB
Volume
81
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Amifostine has the potential to induce h
Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes
✍ Julie Schanz; Heike Jung; Bernhard WΓΆrmann; Winfried Gassmann; Thomas Petersen; πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 260 KB

Myelodysplastic syndromes (MDS) are characterized by hypercellular bone marrow, peripheral cytopenia and an increased rate of intramedullary apoptosis. Oxidative stress is known as an important factor that leads to apoptosis in MDS. Thus, amifostine was investigated in a randomized, multicentre phas